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Letter to the Editor
Letter by Neumann et al Regarding Article, 
“Myostatin Regulates Energy Homeostasis in 
the Heart and Prevents Heart Failure”
To the Editor: 
We read with great interest the article by Biesemann et al1 in 
which the authors uncovered an important role of myostatin and 
myostatin-dependent signaling pathways in the heart for main-
taining cardiac energy homeostasis and preventing cardiac hyper-
trophy. The study is impressive because of the use of a mouse 
model that allows myostatin inactivation in adult cardiomyocytes 
and the amount and quality of collected data. The authors ob-
served that inactivation of myostatin triggers both a metabolic 
switch toward an insulin-independent increase of glycolysis and 
the onset of cardiac hypertrophy. This metabolic switch is argued 
to occur via the increased activity of the energy sensor AMP-
activated kinase (AMPK).
The supposed causal role of AMPK deregulation in cardiac hy-
pertrophy is based mostly on the use of compound C. Compound 
C is a widely used pharmacological inhibitor of AMPK with 
known off-target effects, such as potent inhibition of several other 
kinases (ie, phosphorylase kinase and MAP-kinase–interacting 
kinase).2 Therefore, caution should be taken in deducing AMPK 
involvement from such pharmacological approach. Moreover, 
through genetic models and the use of pharmacological activa-
tors, AMPK has been established as an inhibitor rather than a 
stimulator of cardiac hypertrophy, cell growth and proliferation, 
thus pointing to AMPK activation as a beneficial response mecha-
nism and potential therapeutic strategy for cardiac hypertrophy 
and failure.3,4 Accordingly, we suggest that AMPK, in its function 
as an energy sensor, is more likely to react to the metabolic altera-
tions induced by myostatin ablation. Whether AMPK activation 
is a crucial step in mediating the observed metabolic changes and 
cardiac hypertrophy can be further questioned. In fact, stimula-
tion of AMPK activity in cardiomyocytes simultaneously upregu-
lates glucose and fatty acid uptake as well as their utilization.5 
Hence, a shift toward glucose if mediated by AMPK would re-
quire an unknown mechanism.
The reported increase of glycogen synthase phosphorylation, 
as an established AMPK substrate, turns out as inhibitory phos-
phorylation at Ser641 that is targeted by GSK3 (glycogen syn-
thase kinase 3), another important player in cardiac hypertrophy.6 
The AMPK-dependent phosphorylation of glycogen synthase oc-
curs at serine 7 and is likewise inhibitory to this enzyme.7 Hence, 
the p-GS data do not add to the proposed involvement of AMPK.
The authors identified TAK1 (transforming growth factor β-
activated kinase 1) as an inhibitory kinase of AMPK, which is 
opposite to previous published findings. In particular, cardiac-
specific overexpression of a dominant negative mutant established 
TAK1 as an AMPK-activating kinase in heart and produced a phe-
notype reminiscent to human Wolff–Parkinson–White syndrome.8 
It is difficult to reconcile these data with the Biesemann study.
In the discussion section, one further link is made to PRKAG2 
cardiomyopathy, which is mentioned as mimicking aspects of 
the myostatin phenotype (which refers to myostatin deletion). It 
should be noted that most of the described PRKAG2 mutations on 
the molecular level cause a loss of function rendering AMPK in-
sensitive to AMP, which nevertheless results in increased AMPK 
activity, glycogen storage, and cardiac hypertrophy.9 The reason 
for upregulated AMPK activity in PRKAG2 mutants, since oc-
curring in conjunction with lack of stimulation, remains unclear 
at present.
Instead or besides AMPK there may be a role for protein ki-
nase D signaling in cardiac hypertrophy caused by myostatin ab-
lation, as the authors have shown that transphosphorylation, and 
presumably activity, of this kinase is increased. In this respect, 
protein kinase D1 activation is known to induce a hypertrophic 
programming in the heart via phosphorylation of HDAC5 (his-
tone deacetylase 5) followed by deinhibition of the hypertro-
phic transcription factor MEF2 (myocyte enhancer factor 2).10 
Furthermore, protein kinase D1 activation might explain the re-
ported increases in glucose uptake and utilization, as this kinase 
seems to play a crucial role in GLUT4 (glucose transporter type 
4) translocation without having effects on myocardial fatty acid 
uptake and utilization.11 Accordingly, cardiospecific constitu-
tively active protein kinase D1 overexpression in mice stimulates 
GLUT4 translocation and thereby causes a myocardial substrate 
shift toward glucose.12
In conclusion, cardiac AMPK activation is the safeguard, 
not the culprit causing cardiac hypertrophy, in contrast to the 
authors’ view. Despite disagreement over data interpretation, 
cardiac myostatin overexpression acutely affects AMPK ac-
tivation, as the authors have convincingly shown. Therefore, 
future work should elucidate the changed cardiac energetics 
leading to suppressed AMPK activation (the T172 phosphory-
lation status), such as determining enzyme activities by kinase 
assay and measurements of AMP/ATP ratios backed up by in 
vivo PCr/Cr determinations. The alterations of heart metabo-
lism that were observed on myostatin ablation, in particular 
the shift to glucose, enhanced glucose uptake, glycolysis, and 
the resulting cardiac hypertrophy, rather correspond to known 
effects of AMPK loss of function. Hence, the presented puta-
tive explanatory mechanisms at least deserve further scientific 
discussion.
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